Accession Number : ADA524416


Title :   Vatuximab(Trademark): Optimizing Therapeutic Strategies for Prostate Cancer Based on Dynamic MR Tumor Oximetry


Descriptive Note : Final rept. 15 Nov 2005-31 Dec 2009


Corporate Author : TEXAS UNIV AT DALLAS SOUTHWESTERN MEDICAL CENTER


Personal Author(s) : Mason, Ralph P


Full Text : https://apps.dtic.mil/dtic/tr/fulltext/u2/a524416.pdf


Report Date : Jan 2010


Pagination or Media Count : 61


Abstract : We investigated a novel therapy for prostate cancer using bavituximab, which targets phosphatidylserine expressed on tumor vasculature. Normally, phosphatidylserine exclusively resides on the cytosolic leaflet of the plasma membrane, however, in tumors phosphatidylserine becomes externalized providing a target. It was reported that bavituximab not only targets various tumors, but also induces vascular damage and tumor regression with minimal accompanying toxicity. We found that bavituximab caused little acute pathophysiological response in prostate tumors. Its effect is more subtle than classic vascular disrupting agents. However, in combination with docetaxel there was significantly enhanced tumor growth delay, notably in an intra osseous model of metastatic prostate cancer. Bavituximab is being developed by Peregrine Pharmaceuticals for clinical trials.


Descriptors :   *PROSTATE CANCER , THERAPY , BLOOD VESSELS , NEOPLASMS , ANTIBODIES


Subject Categories : Medicine and Medical Research


Distribution Statement : APPROVED FOR PUBLIC RELEASE